Marine Antitumor Drugs: Status, Shortfalls and Strategies

Overview

Journal Mar Drugs

Publisher MDPI

Specialties Biology
Pharmacology

Date 2010 Dec 1

PMID 21116415

Citations 36

Authors

Ira Bhatnagar

Se-Kwon Kim

Affiliations

Soon will be listed here.

Abstract

Cancer is considered as one of the deadliest diseases in the medical field. Apart from the preventive therapies, it is important to find a curative measure which holds no loopholes and acts accurately and precisely to curb cancer. Over the past few decades, there have been advances in this field and there are many antitumor compounds available on the market, which are of natural as well as synthetic origin. Marine chemotherapy is well recognized nowadays and profound development has been achieved by researchers to deal with different molecular pathways of tumors. However, the marine environment has been less explored for the production of safe and novel antitumor compounds. The reason is a number of shortfalls in this field. Though ample reviews cover the importance and applications of various anticancerous compounds from marine natural products, in the present review, we have tried to bring the current status of antitumor research based on marine inhibitors of cancer signaling pathways. In addition, focus has been placed on the shortfalls and probable strategies in the arena of marine antitumor drug discovery.

Citing Articles

Biochemical evaluation of novel thiazolone derivatives as dual α-glucosidase/α-amylase inhibitors, anti-inflammatory agents.

Abdelhamid M, Eraky S, El-Deen I, Elian Sophy M Future Med Chem. 2025; 17(2):209-219.

PMID: 39829378 PMC: 11749350. DOI: 10.1080/17568919.2024.2447225.

Pharmacophore-based virtual screening, molecular docking, and molecular dynamics investigation for the identification of novel, marine aromatase inhibitors.

Kotb M, Abdelmawgood I, Ibrahim I BMC Chem. 2024; 18(1):235.

PMID: 39593184 PMC: 11590544. DOI: 10.1186/s13065-024-01350-9.

Synthesis and biological evaluation of biotinylated ZJ-101.

Qian S, Head S, Sanchez P, Liu J, Jin Z Bioorg Med Chem Lett. 2023; 91:129372.

PMID: 37301523 PMC: 10330923. DOI: 10.1016/j.bmcl.2023.129372.

Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics.

Sharma A, Sharma D, Saini N, Sharma S, Thakur V, Goyal R Cancer Metastasis Rev. 2023; 42(3):847-889.

PMID: 37204562 PMC: 10584807. DOI: 10.1007/s10555-023-10106-1.

spp.: Secondary Metabolites, Pharmacological Activities, and Mechanisms.

Hadisaputri Y, Nurhaniefah A, Sukmara S, Zuhrotun A, Hendriani R, Sopyan I Metabolites. 2023; 13(2).

PMID: 36837836 PMC: 9964934. DOI: 10.3390/metabo13020217.

References

Goulaouic H, Roulon T, Flamand O, Grondard L, Lavelle F, Riou J . Purification and characterization of human DNA topoisomerase IIIalpha. Nucleic Acids Res. 1999; 27(12):2443-50. PMC: 148446. DOI: 10.1093/nar/27.12.2443. View

Okouneva T, Azarenko O, Wilson L, Littlefield B, Jordan M . Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther. 2008; 7(7):2003-11. PMC: 2562299. DOI: 10.1158/1535-7163.MCT-08-0095. View

Dassonneville L, Wattez N, Baldeyrou B, Mahieu C, Lansiaux A, Banaigs B . Inhibition of topoisomerase II by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells. Biochem Pharmacol. 2000; 60(4):527-37. DOI: 10.1016/s0006-2952(00)00351-8. View

Jackson K, Henderson J, Phillips A . The halichondrins and E7389. Chem Rev. 2009; 109(7):3044-79. DOI: 10.1021/cr900016w. View

Du L, Feng T, Zhao B, Li D, Cai S, Zhu T . Alkaloids from a deep ocean sediment-derived fungus Penicillium sp. and their antitumor activities. J Antibiot (Tokyo). 2010; 63(4):165-70. DOI: 10.1038/ja.2010.11. View

Baldwin Jr A . The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996; 14:649-83. DOI: 10.1146/annurev.immunol.14.1.649. View

Olano C, Mendez C, Salas J . Antitumor compounds from marine actinomycetes. Mar Drugs. 2009; 7(2):210-48. PMC: 2707044. DOI: 10.3390/md7020210. View

Liu R, Liu Y, Zhou Y, Nagle D . Molecular-targeted antitumor agents. 15. Neolamellarins from the marine sponge Dendrilla nigra inhibit hypoxia-inducible factor-1 activation and secreted vascular endothelial growth factor production in breast tumor cells. J Nat Prod. 2007; 70(11):1741-5. PMC: 2914556. DOI: 10.1021/np070206e. View

Semenza G . HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002; 8(4 Suppl):S62-7. DOI: 10.1016/s1471-4914(02)02317-1. View

10.

Kim M, Van Ta Q, Mendis E, Rajapakse N, Jung W, Byun H . Phlorotannins in Ecklonia cava extract inhibit matrix metalloproteinase activity. Life Sci. 2006; 79(15):1436-43. DOI: 10.1016/j.lfs.2006.04.022. View

11.

Hodges T, Hossain C, Kim Y, Zhou Y, Nagle D . Molecular-targeted antitumor agents: the Saururus cernuus dineolignans manassantin B and 4-O-demethylmanassantin B are potent inhibitors of hypoxia-activated HIF-1. J Nat Prod. 2004; 67(5):767-71. DOI: 10.1021/np030514m. View

12.

Van Ta Q, Kim M, Kim S . Inhibitory effect of chitooligosaccharides on matrix metalloproteinase-9 in human fibrosarcoma cells (HT1080). Mar Biotechnol (NY). 2006; 8(6):593-9. DOI: 10.1007/s10126-006-6031-7. View

13.

Tardy C, Facompre M, Laine W, Baldeyrou B, Garcia-Gravalos D, Francesch A . Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues. Bioorg Med Chem. 2004; 12(7):1697-712. DOI: 10.1016/j.bmc.2004.01.020. View

14.

Hassan H, Khanfar M, Elnagar A, Mohammed R, Shaala L, Youssef D . Pachycladins A-E, prostate cancer invasion and migration inhibitory Eunicellin-based diterpenoids from the red sea soft coral Cladiella pachyclados. J Nat Prod. 2010; 73(5):848-53. DOI: 10.1021/np900787p. View

15.

Bonnard I, Bontemps N, Lahmy S, Banaigs B, Combaut G, Francisco C . Binding to DNA and cytotoxic evaluation of ascididemin, the major alkaloid from the Mediterranean ascidian Cystodytes dellechiajei. Anticancer Drug Des. 1995; 10(4):333-46. View

16.

Bringmann G, Gulder T, Lang G, Schmitt S, Stohr R, Wiese J . Large-scale biotechnological production of the antileukemic marine natural product sorbicillactone A. Mar Drugs. 2008; 5(2):23-30. PMC: 2365691. DOI: 10.3390/md502023. View

17.

Nicholson B, Lloyd G, Miller B, Palladino M, Kiso Y, Hayashi Y . NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2005; 17(1):25-31. DOI: 10.1097/01.cad.0000182745.01612.8a. View

18.

Wang Y, Lyu Y, Wang J . Dual localization of human DNA topoisomerase IIIalpha to mitochondria and nucleus. Proc Natl Acad Sci U S A. 2002; 99(19):12114-9. PMC: 129407. DOI: 10.1073/pnas.192449499. View

19.

Keck G, Poudel Y, Welch D, Kraft M, Truong A, Stephens J . Substitution on the A-ring confers to bryopyran analogues the unique biological activity characteristic of bryostatins and distinct from that of the phorbol esters. Org Lett. 2008; 11(3):593-6. PMC: 2647801. DOI: 10.1021/ol8027253. View

20.

Gorajana A, Venkatesan M, Vinjamuri S, Kurada B, Peela S, Jangam P . Resistoflavine, cytotoxic compound from a marine actinomycete, Streptomyces chibaensis AUBN1/7. Microbiol Res. 2006; 162(4):322-7. DOI: 10.1016/j.micres.2006.01.012. View